

# Maria Concetta Fagnoli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5864800/publications.pdf>

Version: 2024-02-01

166  
papers

6,004  
citations

76326

40  
h-index

91884

69  
g-index

167  
all docs

167  
docs citations

167  
times ranked

6548  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study. Archives of Dermatological Research, 2022, 314, 593-603.	1.9	8
2	Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic. Clinical and Experimental Dermatology, 2022, 47, 165-167.	1.3	23
3	A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	12
4	Melanoma in children and adolescents: analysis of susceptibility genes in 123 Italian patients. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 213-221.	2.4	8
5	Dimethyl Fumarate's Effectiveness and Safety in Psoriasis: A Real-Life Experience During the COVID-19 Pandemic. Dermatology and Therapy, 2022, 12, 671-681.	3.0	5
6	Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1292-1299.	2.4	23
7	Sharing Patient and Clinician Experiences of Moderate-to-Severe Psoriasis: A Nationwide Italian Survey and Expert Opinion to Explore Barriers Impacting upon Patient Wellbeing. Journal of Clinical Medicine, 2022, 11, 2801.	2.4	6
8	Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year. Expert Opinion on Biological Therapy, 2022, 22, 1585-1592.	3.1	5
9	Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline " Update 2022. European Journal of Cancer, 2022, 171, 203-231.	2.8	51
10	Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. Journal of Dermatological Treatment, 2021, 32, 507-513.	2.2	67
11	<i>MC1R</i> variants in relation to naevi in melanoma cases and controls: a pooled analysis from the M&SKIP project. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e135-e138.	2.4	3
12	Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study. Expert Opinion on Biological Therapy, 2021, 21, 271-277.	3.1	40
13	Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 958-964.	2.4	66
14	A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e169-e170.	2.4	31
15	Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 693-700.	2.4	26
16	Cutaneous and Mucosal Melanomas of Uncommon Sites: Where Do We Stand Now?. Journal of Clinical Medicine, 2021, 10, 478.	2.4	12
17	Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA&COVID-19 registry. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1813-1824.	5.7	28
18	Satisfaction and attitudes toward systemic treatments for psoriasis: A cross-sectional study. Dermatologic Therapy, 2021, 34, e14949.	1.7	4

#	ARTICLE	IF	CITATIONS
19	Pigmented lesions with unusual penile localisation: Usefulness of reflectance confocal microscopy â€• Report of 2 cases. Australasian Journal of Dermatology, 2021, 62, e456-e458.	0.7	1
20	Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four PhaseÂ3 Trials. Dermatology and Therapy, 2021, 11, 1357-1372.	3.0	19
21	Molecular alterations in basal cell carcinoma subtypes. Scientific Reports, 2021, 11, 13206.	3.3	19
22	Sequential treatment with calcitriol and methyl aminolevulinate-daylight photodynamic therapy for patients with multiple actinic keratoses of the upper extremities. Photodiagnosis and Photodynamic Therapy, 2021, 34, 102325.	2.6	8
23	Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16â€week realâ€life experience during the <scp>COVID</scp> â€19 pandemic in Italy. Dermatologic Therapy, 2021, 34, e15035.	1.7	24
24	Clinical determinants of complete response to vismodegib in locally advanced basal cell carcinoma: a multicentre experience. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e923-e926.	2.4	2
25	Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2149-2153.	2.4	14
26	Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1949-1956.	2.4	10
27	Risk of infections in psoriasis: assessment and challenges in daily management. Expert Review of Clinical Immunology, 2021, 17, 1211-1220.	3.0	2
28	Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy. Patient Preference and Adherence, 2021, Volume 15, 2551-2562.	1.8	3
29	Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis. Journal of Dermatological Treatment, 2020, 31, 692-697.	2.2	5
30	Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series. Postgraduate Medicine, 2020, 132, 172-175.	2.0	4
31	Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. Expert Review of Clinical Immunology, 2020, 16, 119-128.	3.0	12
32	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment â€• Update 2019. European Journal of Cancer, 2020, 126, 159-177.	2.8	154
33	Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 932-941.	2.4	33
34	Response to: Comment on â€•Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelinesâ€™. European Journal of Cancer, 2020, 140, 154-157.	2.8	1
35	Management of biological therapies for chronic plaque psoriasis during COVIDâ€19 emergency in Italy. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e770-e772.	2.4	31
36	Patientsâ€™ demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis. PLoS ONE, 2020, 15, e0237267.	2.5	19

#	ARTICLE	IF	CITATIONS
37	Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2839-2845.	2.4	6
38	Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis. <i>Dermatology</i> , 2020, 236, 329-335.	2.1	9
39	Italian expert consensus paper on the management of patients with actinic keratoses. <i>Dermatologic Therapy</i> , 2020, 33, e13992.	1.7	12
40	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. <i>European Journal of Cancer</i> , 2020, 128, 60-82.	2.8	131
41	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. <i>European Journal of Cancer</i> , 2020, 128, 83-102.	2.8	181
42	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 141-158.	2.8	133
43	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. <i>Nature Genetics</i> , 2020, 52, 494-504.	21.4	138
44	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. <i>European Journal of Cancer</i> , 2020, 134, 19-28.	2.8	45
45	Coding and noncoding somatic mutations in candidate genes in basal cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 8005.	3.3	17
46	Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. <i>European Journal of Cancer</i> , 2019, 118, 10-34.	2.8	345
47	Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis. <i>Case Reports in Dermatology</i> , 2019, 11, 1-3.	0.8	4
48	Contribution of Common Genetic Variants to Familial Aggregation of Disease and Implications for Sequencing Studies. <i>PLoS Genetics</i> , 2019, 15, e1008490.	3.5	8
49	Single versus two-treatment schedule of methyl aminolevulinate daylight photodynamic therapy for actinic keratosis of the face and scalp: An intra-patient randomized trial. <i>Photodiagnosis and Photodynamic Therapy</i> , 2019, 27, 100-104.	2.6	9
50	Dermoscopic similarity is an independent predictor of <i>BRAF</i> mutational concordance in multiple melanomas. <i>Experimental Dermatology</i> , 2019, 28, 829-835.	2.9	4
51	Telomeres and Telomerase in Cutaneous Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1333.	4.1	13
52	MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 332-342.	5.6	16
53	Familial Melanoma: Diagnostic and Management Implications. <i>Dermatology Practical and Conceptual</i> , 2019, 9, 10-16.	0.9	57
54	Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. <i>British Journal of Dermatology</i> , 2019, 180, 1547-1548.	1.5	30

#	ARTICLE	IF	CITATIONS
55	Sclerosing nevus with pseudomelanomatous features: dermoscopic and confocal aspects. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 525-532.	2.4	2
56	Prevalence of cutaneous comorbidities in psoriatic patients and their impact on quality of life. <i>European Journal of Dermatology</i> , 2019, 29, 192-196.	0.6	9
57	Interferon-beta injection site reactions in patients with multiple sclerosis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 831-834.	2.2	8
58	Clinical, dermoscopic, and confocal features of nevi and melanomas in a multiple primary melanoma patient with the MITF p.E318K homozygous mutation. <i>Melanoma Research</i> , 2018, 28, 166-169.	1.2	11
59	Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 110-122.	2.8	22
60	Patient and physician satisfaction in an observational study with methyl aminolevulinate daylight photodynamic therapy in the treatment of multiple actinic keratoses of the face and scalp in six European countries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 757-762.	2.4	18
61	Prevalence of pathogenic/likely pathogenic variants in the 24 cancer genes of the ACMG Secondary Findings v2.0 list in a large cancer cohort and ethnicity-matched controls. <i>Genome Medicine</i> , 2018, 10, 99.	8.2	15
62	Long-term efficacy data for daylight-PDT. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2018, 153, 800-805.	0.8	5
63	Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 727-735.	3.1	52
64	Combining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma. <i>Human Molecular Genetics</i> , 2018, 27, 4145-4156.	2.9	34
65	MelaNostrum: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the melanostrum consortium. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2134-2141.	2.4	9
66	&em&gt;MC1R&lt;/em&gt; variants as melanoma risk factors independent of at-risk phenotypic characteristics: a pooled analysis from the M-SKIP project. <i>Cancer Management and Research</i> , 2018, Volume 10, 1143-1154.	1.9	57
67	A new dermoscopic algorithm for the differential diagnosis of facial lentigo maligna and pigmented actinic keratosis. <i>European Journal of Dermatology</i> , 2018, 28, 162-168.	0.6	19
68	HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 295-301.	3.8	13
69	Characterization of melanoma susceptibility genes in high-risk patients from Central Italy. <i>Melanoma Research</i> , 2017, 27, 258-267.	1.2	29
70	Long-term efficacy and safety of daylight photodynamic therapy with methyl aminolevulinate for actinic keratosis of the face and scalp. <i>European Journal of Dermatology</i> , 2017, 27, 89-91.	0.6	12
71	Drug-induced eruptive melanocytic nevi. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 293-300.	3.3	9
72	Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics. <i>European Journal of Dermatology</i> , 2017, 27, 599-608.	0.6	30

#	ARTICLE	IF	CITATIONS
73	Understanding the Molecular Genetics of Basal Cell Carcinoma. International Journal of Molecular Sciences, 2017, 18, 2485.	4.1	154
74	Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments. PLoS ONE, 2017, 12, e0183415.	2.5	27
75	Risk of second primary malignancies among 1537 melanoma patients and risk of second primary melanoma among 52 354 cancer patients in Northern Italy. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1491-1496.	2.4	20
76	Real-life efficacy and safety of ingenol mebutate for the treatment of actinic keratosis of the face and scalp: A single arm retrospective study. Journal of Dermatological Treatment, 2016, 27, 525-530.	2.2	11
77	Association of Melanocortin-1 Receptor Variants with Pigmentary Traits in Humans: A Pooled Analysis from the M-Skip Project. Journal of Investigative Dermatology, 2016, 136, 1914-1917.	0.7	16
78	Conventional Treatment of Actinic Keratosis: An Overview. Current Problems in Dermatology, 2015, 46, 108-114.	0.7	8
79	MC1R variants increased the risk of sporadic cutaneous melanoma in darker pigmented Caucasians: A pooled analysis from the M-SKIP project. International Journal of Cancer, 2015, 136, 618-631.	5.1	92
80	Association of psoriasis and/or psoriatic arthritis with autoimmune diseases: the experience of two Italian integrated Dermatology/Rheumatology outpatient clinics. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2160-2168.	2.4	13
81	Photodynamic therapy for basal cell carcinoma. Future Oncology, 2015, 11, 2991-2996.	2.4	25
82	Differences in Clinicopathological Features and Distribution of Risk Factors in Italian Melanoma Patients. Dermatology, 2015, 230, 256-262.	2.1	6
83	MC1R gene variants and non-melanoma skin cancer: a pooled-analysis from the M-SKIP project. British Journal of Cancer, 2015, 113, 354-363.	6.4	43
84	Dermoscopic variability of basal cell carcinoma according to clinical type and anatomic location. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1732-1741.	2.4	53
85	Conventional vs. daylight methyl aminolevulinate photodynamic therapy for actinic keratosis of the face and scalp: an intra-patient, prospective, comparison study in Italy. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1926-1932.	2.4	59
86	The first skin cancer screening day at the Italian parliament: a melanoma initiative. International Journal of Dermatology, 2015, 54, 42-49.	1.0	3
87	Rationale for the Development of Speckled Hyperpigmentation in the Areas of Psoriatic Plaques after Treatment with Biologic Agents. Journal of Investigative Dermatology, 2015, 135, 318-320.	0.7	13
88	Photodynamic therapy for the treatment of microinvasive squamous cell carcinoma of the lower lip: a case report. Giornale Italiano Di Dermatologia E Venereologia, 2015, 150, 331-5.	0.8	11
89	Association of Genetic Variants in CDK6 and XRCC1 with the Risk of Dysplastic Nevi in Melanoma-Prone Families. Journal of Investigative Dermatology, 2014, 134, 481-487.	0.7	10
90	Selective sunscreen application on nevi: frequency and determinants of a wrong sun-protective behaviour. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 348-354.	2.4	5

#	ARTICLE	IF	CITATIONS
91	Dermoscopic features and follow-up changes of acral melanocytic naevi in childhood and adolescence. <i>British Journal of Dermatology</i> , 2014, 170, 374-381.	1.5	12
92	Dermoscopic features of cutaneous melanoma are associated with clinical characteristics of patients and tumours and with <i>MC1R</i> genotype. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1768-1775.	2.4	16
93	Rare missense variants in <i>POT1</i> predispose to familial cutaneous malignant melanoma. <i>Nature Genetics</i> , 2014, 46, 482-486.	21.4	283
94	Skin cancer risk in autoimmune connective tissue diseases. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2014, 149, 567-72.	0.8	3
95	Knowledge, perceptions and behaviours about skin cancer and sun protection among secondary school students from Central Italy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 571-579.	2.4	32
96	Frequency of melanocytic nevi in psoriatic patients is related to treatment and not to disease severity. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 947-953.	1.2	12
97	A variant in <i>FTO</i> shows association with melanoma risk not due to BMI. <i>Nature Genetics</i> , 2013, 45, 428-432.	21.4	111
98	Dermoscopy in the diagnosis and management of non-melanoma skin cancers. <i>European Journal of Dermatology</i> , 2012, 22, 456-463.	0.6	67
99	The spectrum of dermatoscopic patterns in blue nevi. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 199-205.	1.2	41
100	<i>MC1R</i> , <i>SLC45A2</i> and <i>TYR</i> genetic variants involved in melanoma susceptibility in Southern European populations: Results from a Meta-analysis. <i>European Journal of Cancer</i> , 2012, 48, 2183-2191.	2.8	40
101	<i>MC1R</i> variants predisposing to concomitant primary cutaneous melanoma in a monozygotic twin pair. <i>BMC Medical Genetics</i> , 2012, 13, 81.	2.1	2
102	Melanocortin-1 receptor, skin cancer and phenotypic characteristics (M-SKIP) project: study design and methods for pooling results of genetic epidemiological studies. <i>BMC Medical Research Methodology</i> , 2012, 12, 116.	3.1	12
103	Current psoriasis treatments in an Italian population and their association with socio-demographical and clinical features. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 976-982.	2.4	15
104	On the Interplay of Telomeres, Nevi and the Risk of Melanoma. <i>PLoS ONE</i> , 2012, 7, e52466.	2.5	18
105	Rapid response of scalp psoriasis to ustekinumab. <i>European Journal of Dermatology</i> , 2011, 21, 993-994.	0.6	13
106	Mesalazine-induced psoriasis in patients with inflammatory bowel diseases. <i>European Journal of Dermatology</i> , 2011, 21, 784-785.	0.6	2
107	<i>EDNRB</i> gene variants and melanoma risk in two southern European populations. <i>Clinical and Experimental Dermatology</i> , 2011, 36, 782-787.	1.3	4
108	Vascular patterns in basal cell carcinoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 358-361.	2.4	52



#	ARTICLE	IF	CITATIONS
109	Efficacy and tolerability of 5-aminolevulinic acid 0.5% liposomal spray and intense pulsed light in wrinkle reduction of photodamaged skin. <i>Journal of Dermatological Treatment</i> , 2011, 22, 247-253.	2.2	22
110	Pigmented reticular structures in basal cell carcinoma and collision tumours. <i>British Journal of Dermatology</i> , 2010, 162, 442-444.	1.5	11
111	Dermoscopic Evolution of Vascular Pattern in Two Cases of Amelanotic Melanoma. <i>Acta Dermato-Venereologica</i> , 2010, 90, 83-85.	1.3	5
112	Dermatoscopy of basal cell carcinoma: Morphologic variability of global and local features and accuracy of diagnosis. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 67-75.	1.2	264
113	MC1R variants increase melanoma risk in families with CDKN2A mutations: A meta-analysis. <i>European Journal of Cancer</i> , 2010, 46, 1413-1420.	2.8	92
114	Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy. <i>International Journal of Hematology</i> , 2009, 89, 76-79.	1.6	8
115	Variants of the xeroderma pigmentosum variant gene (POLH) are associated with melanoma risk. <i>European Journal of Cancer</i> , 2009, 45, 3228-3236.	2.8	38
116	Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant. <i>European Journal of Cancer</i> , 2009, 45, 3054-3063.	2.8	123
117	Nucleotide diversity and population differentiation of the Melanocortin 1 Receptor gene, MC1R. <i>BMC Genetics</i> , 2008, 9, 31.	2.7	29
118	MC1R variants, melanoma and red hair color phenotype: A meta-analysis. <i>International Journal of Cancer</i> , 2008, 122, 2753-2760.	5.1	304
119	MC1R Variants Increase Risk of Melanomas Harboring BRAF Mutations. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2485-2490.	0.7	78
120	Efalizumab-induced immune thrombocytopenia during retreatment. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, S125-S127.	1.2	6
121	No Evidence for Linkage with Melanoma in Italian Melanoma-Prone Families. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1838-1840.	2.5	2
122	Effective control of psoriasis by etanercept in a patient with HCV-related diseases. <i>European Journal of Dermatology</i> , 2008, 18, 459-60.	0.6	10
123	Dermoscopic Changes in Acral Melanocytic Nevi During Digital Follow-up. <i>Archives of Dermatology</i> , 2007, 143, 1372-6.	1.4	28
124	Dermoscopic features of actinic keratosis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2007, 5, 970-975.	0.8	79
125	Comprehensive evaluation of allele frequency differences of MC1R variants across populations. <i>Human Mutation</i> , 2007, 28, 495-505.	2.5	135
126	Family history of psoriasis and age at disease onset in Italian patients with psoriasis. <i>British Journal of Dermatology</i> , 2007, 156, 1400-1401.	1.5	23



#	ARTICLE	IF	CITATIONS
127	The additive value of second opinion teleconsulting in the management of patients with challenging inflammatory, neoplastic skin diseases: a best practice model in dermatology?. Journal of the European Academy of Dermatology and Venereology, 2007, 21, 30-34.	2.4	50
128	Letter: Changes in Dermoscopic Features in Superficial Basal Cell Carcinomas Treated with Imiquimod. Dermatologic Surgery, 2007, 33, 1403-1405.	0.8	25
129	Efficacy of photodynamic therapy with methyl aminolevulinat in the treatment of superficial and nodular basal cell carcinoma: an open-label trial. European Journal of Dermatology, 2007, 17, 412-5.	0.6	29
130	Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma. Journal of the American Academy of Dermatology, 2006, 55, 324-327.	1.2	81
131	Usefulness of Dermoscopy to Monitor Clinical Efficacy of Imiquimod Treatment for Lentigo Maligna. Archives of Dermatology, 2006, 142, 530.	1.4	29
132	Contribution of melanocortin-1 receptor gene variants to sporadic cutaneous melanoma risk in a population in central Italy: a case-control study. Melanoma Research, 2006, 16, 175-182.	1.2	42
133	Hypoepiluminescence Microscopy of Pigmented Skin Lesions: New Approach to Improve Recognition of Dermoscopic Structures. Dermatologic Surgery, 2006, 32, 1391-1397.	0.8	3
134	The A148T Variant of the CDKN2A Gene Is Not Associated with Melanoma Risk in the French and Italian Populations. Journal of Investigative Dermatology, 2006, 126, 1657-1660.	0.7	26
135	Dermoscopic Patterns of Acral Melanocytic Nevi and Melanomas in a White Population in Central Italy. Archives of Dermatology, 2006, 142, 1123-8.	1.4	85
136	Re: MC1R, ASIP, and DNA Repair in Sporadic and Familial Melanoma in a Mediterranean Population. Journal of the National Cancer Institute, 2006, 98, 144-145.	6.3	21
137	High- and low-penetrance cutaneous melanoma susceptibility genes. Expert Review of Anticancer Therapy, 2006, 6, 657-670.	2.4	45
138	Topical Tazarotene 0.05% versus Glycolic Acid 70% Treatment in X-linked Ichthyosis due to Extensive Deletion of the STS Gene. Acta Dermato-Venereologica, 2005, -1, 1-1.	1.3	2
139	Giant Dermatofibroma Appearing During Pregnancy. Acta Dermato-Venereologica, 2005, -1, 1-1.	1.3	6
140	Acanthosis Nigricans. New England Journal of Medicine, 2005, 353, 2797-2797.	27.0	7
141	Efficacy of Treatment With Tetracyclines to Prevent Acneiform Eruption Secondary to Cetuximab Therapy. Archives of Dermatology, 2005, 141, 1173-4.	1.4	27
142	Cutaneous Manifestations in Italian Kidney Transplant Recipients. Transplantation Proceedings, 2005, 37, 2527-2528.	0.6	39
143	Psoriasis, Kaposi's Sarcoma and Hodgkin's Disease in a Patient with Down's Syndrome. Dermatology, 2004, 209, 158-159.	2.1	10
144	CDKN2A and MC1R Mutations in Patients with Sporadic Multiple Primary Melanoma. Journal of Investigative Dermatology, 2004, 122, 1327-1330.	0.7	24

#	ARTICLE	IF	CITATIONS
145	Constitutional and environmental risk factors for cutaneous melanoma in an Italian population. A caseâ€control study. <i>Melanoma Research</i> , 2004, 14, 151-157.	1.2	37
146	Cutaneous Amelanotic Melanoma Metastasis and Dermatofibromas Showing a Dotted Vascular Pattern. <i>Acta Dermato-Venereologica</i> , 2004, 84, 164-165.	1.3	8
147	Identification of four novel melanocortin 1 receptor (MC1R) gene variants in a Mediterranean population. <i>Human Mutation</i> , 2003, 21, 655-655.	2.5	26
148	Microabrasion Versus Microabrasion Followed by 15% Trichloroacetic Acid for Treatment of Cutaneous Hyperpigmentations in Adult Females. <i>Dermatologic Surgery</i> , 2003, 29, 352-356.	0.8	13
149	Disseminated Pagetoid Reticulosis Presenting as Cytotoxic CD4/CD8 Double Negative Cutaneous T-cell Lymphoma. <i>Acta Dermato-Venereologica</i> , 2002, 82, 314-316.	1.3	7
150	Efficacy Evaluation of an Oil-in-Water Emulsion (Dermoflan) in Atopic Dermatitis. <i>Acta Dermato-Venereologica</i> , 2002, 82, 465-466.	1.3	11
151	Interobserver Agreement on Dermoscopic Features of Pigmented Basal Cell Carcinoma. <i>Dermatologic Surgery</i> , 2002, 28, 643-645.	0.8	53
152	Lessons on Dermoscopy. <i>Dermatologic Surgery</i> , 2002, 28, 540-541.	0.8	0
153	Lessons on Dermoscopy. <i>Dermatologic Surgery</i> , 2002, 28, 440-441.	0.8	0
154	Granulomatous mycosis fungoides responsive to gemcitabine. <i>European Journal of Dermatology</i> , 2002, 12, 479-81.	0.6	3
155	Mucosal involvement in a patient with lymphomatoid papulosis. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 339-341.	1.2	35
156	Unusually Large Cutaneous Metastases of Renal Cell Carcinoma. <i>Acta Dermato-Venereologica</i> , 2001, 81, 77-78.	1.3	16
157	Preliminary Observations on the Use of Topical Tazarotene to Treat Basal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 1999, 341, 1767-1768.	27.0	84
158	UV Fingerprint CDKN2a but No p14ARF Mutations in Sporadic Melanomas. <i>Journal of Investigative Dermatology</i> , 1999, 112, 825-826.	0.7	21
159	The Use of Chemical Peelings in the Treatment of Different Cutaneous Hyperpigmentations. <i>Dermatologic Surgery</i> , 1999, 25, 450-454.	0.8	59
160	Reduced expression of CDKN2a/p16 INK4a in mycosis fungoides. <i>Archives of Dermatological Research</i> , 1999, 291, 207-211.	1.9	20
161	CDKN2a/p16INK4a Mutations and Lack of p19ARF Involvement in Familial Melanoma Kindreds. <i>Journal of Investigative Dermatology</i> , 1998, 111, 1202-1206.	0.7	65
162	Peripheral nervous system involvement in a patient with large T-cell lymphoma arising from a pre-existing mycosis fungoides. <i>British Journal of Dermatology</i> , 1998, 139, 299-301.	1.5	21

#	ARTICLE	IF	CITATIONS
163	Clinicopathologic findings in the Bannayan-Riley-Ruvalcaba syndrome. Archives of Dermatology, 1996, 132, 1214-1218.	1.4	79
164	Use of recombinant interferon alpha-2a in the treatment of squamous cell carcinoma. Journal of Dermatological Treatment, 1995, 6, 163-166.	2.2	2
165	Pentachrome vitiligo. Journal of the American Academy of Dermatology, 1995, 33, 853-856.	1.2	24
166	Effects of Ultraviolet Irradiation on the Cell Cycle. Pigment Cell & Melanoma Research, 1994, 7, 320-325.	3.6	16